Quarterly ResultMay 7, 2026, 07:33 AM
Collegium Q1 Net Revenue $193.5M, Up 9%; JORNAY PM Revenue Up 36%
AI Summary
Collegium Pharmaceutical reported strong financial results for the first quarter ended March 31, 2026, with total net revenues increasing 9% year-over-year to $193.5 million. The company's JORNAY PM product saw significant growth, with net revenue up 36% to $38.9 million, and the pain portfolio also delivered solid performance with a 4% increase to $154.6 million. Collegium reaffirmed its full-year 2026 guidance for its current business and remains on track to close the acquisition of AZSTARYS in the second quarter of 2026, which is expected to strengthen its ADHD portfolio and be immediately accretive.
Key Highlights
- Generated Quarterly Net Revenues of $193.5 million, up 9% year-over-year.
- JORNAY PM Quarterly Net Revenue reached $38.9 million, up 36% year-over-year.
- Pain Portfolio Net Revenues were $154.6 million, up 4% year-over-year.
- GAAP Net Income for Q1'26 was $14.5 million, compared to $2.4 million in Q1'25.
- Adjusted EBITDA for Q1'26 was $103.9 million, a 9% increase year-over-year.
- Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 million.
- On track to close the acquisition of AZSTARYS in the second quarter of 2026.
- Reaffirmed full-year 2026 guidance for current business: Product Revenues $805-$825M, JORNAY PM Revenue $190-$200M, Adjusted EBITDA $455-$475M.